. .
.
Ključne reči:
.
Sažetak
.
Reference
Reference
[1] Li X, Guo X, Chang Y, et al. Analysis of alterations of serum inflammatory cyto-kines and fibrosis makers in patients with essential hypertension and left ventricular hypertrophy and the risk factors[J]. Am J Transl Res, 2022, 14:4097-4103.
[2] Chen Y, Zhao Y, Yuan L, et al. Periplaneta americana extract attenuates hepatic fibrosis progression by inhibiting collagen synthesis and regulating the TGF-β1/Smad signaling pathway[J]. Folia Histochem Cytobiol, 2023, 61:231-243.
[3] Tang X, Yang L, Zhang P, et al. Occult Hepatitis B Virus Infection and Liver Fi-brosis in Chinese Patients[J]. J Infect Dis, 2023, 228:1375-1384.
[4] Diemar SS, Dahl SS, West AS, et al. A Systematic Review of the Circadian Rhythm of Bone Markers in Blood[J]. Calcif Tissue Int, 2023, 112:126-147.
[5] He Y, Gu X, Yang Z, et al. Study on the mechanism underlying Trichosanthis peel injection-induced improvements in myocardial fibrosis markers in patients with chronic heart failure[J]. Clin Exp Pharmacol Physiol, 2024, 51:e13848.
[6] Moufarrej MN, Vorperian SK, Wong RJ, et al. Early prediction of preeclampsia in pregnancy with cell-free RNA[J]. Nature, 2022, 602:689-694.
[7] Su Y, Wang W, Liu F, et al. Blosozumab in the treatment of postmenopausal women with osteoporosis: a systematic review and meta-analysis[J]. Ann Palliat Med, 2022, 11:3203-3212.
[8] Li H, Xu X, Yi T, et al. Expression of chitinase-3-like protein 1 in different TCM syndromes and its correlation with liver fibrosis[J]. Ann Palliat Med, 2022, 11:217-224.
[9] Fan J, Li Y, Yan Q, et al. Higher serum sST2 is associated with increased left atri-al low-voltage areas and atrial fibrillation recurrence in patients undergoing radiof-requency ablation[J]. J Interv Card Electrophysiol, 2022, 64:733-742.
[10] Chen XF, Ji S. Sorafenib Attenuates Fibrotic Hepatic Injury Through Mediating Lysine Crotonylation[J]. Drug Des Devel Ther, 2022, 16:2133-2144.
[11] Huang Q, Zhang K, Li Y, et al. Auto- and Hetero-Catalytic Processing of the N-Terminal Propeptide Promotes the C-Terminal Fibronectin Type III Domain-Mediated Dimerization of a Thermostable Vpr-like Protease[J]. Appl Environ Micro-biol, 2022, 88:e0150322.
[12] Matsumoto T, Sone T, Soen S, et al. Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study[J]. J Clin Endocrinol Metab, 2022, 107:e4222-e4231.
[13] Malecki-Ketchell A. Acute coronary syndrome: role of the nurse in patient as-sessment and management[J]. Nurs Stand, 2022, 37:69-75.
[14] Wang S, Meng F, Li M, et al. Multidimensional Cell-Free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer[J]. Am J Respir Crit Care Med, 2023, 207:1203-1213.
[15] Ćorović A, Wall C, Nus M, et al. Somatostatin Receptor PET/MR Imaging of Inflammation in Patients With Large Vessel Vasculitis and Atherosclerosis[J]. J Am Coll Cardiol, 2023, 81:336-354.
[16] Tokumoto M, Tokunaga S, Asada S, et al. Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism[J]. PLoS One, 2022, 17:e0279078.
[17] Gadelha MR, Gordon MB, Doknic M, et al. ACROBAT Edge: Safety and Effi-cacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly[J]. J Clin Endocrinol Metab, 2023, 108:e148-e159.
[18] Papadimitriou MA, Levis P, Kotronopoulos G, et al. Preoperative Cell-Free DNA (cfDNA) in Muscle-Invasive Bladder Cancer Treatment Outcome[J]. Clin Chem, 2023, 69:399-410.
[19] Vasikaran SD, Miura M, Pikner R, et al. Practical Considerations for the Clinical Application of Bone Turnover Markers in Osteoporosis[J]. Calcif Tissue Int, 2023, 112:148-157.
[20] Zhu Y, Pei L, Li N, et al. Preoperative sST2 levels relate to myocardial remodel-ing and cardiac function improvement after cardiac valve surgery[J]. ESC Heart Fail, 2024, 11:91-98.
[21] Chen Y, Zhao X, Liang L, et al. sST2 and Big ET-1 as Alternatives of Multi-Biomarkers Strategies for Prognosis Evaluation in Patients Hospitalized with Heart Failure[J]. Int J Gen Med, 2023, 16:5003-5016.
[22] Tang LJ, Li G, Eslam M, et al. N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD[J]. Hepatol Int, 2023, 17:190-201.
[23] Tominaga A, Wada K, Okazaki K, et al. Nonresponder Considerations for Ro-mosozumab Treatment[J]. Calcif Tissue Int, 2023, 113:157-165.
[24] Meng Q, Zhang M. Clinical Significance of Serum Collagen Type IV and Pro-collagen Type III N-Peptide Levels in Diagnosis and Differential Diagnosis of Lymphedema[J]. Lymphat Res Biol, 2023, 21:8-14.
[25] Esfahani MS, Hamilton EG, Mehrmohamadi M, et al. Inferring gene expression from cell-free DNA fragmentation profiles[J]. Nat Biotechnol, 2022, 40:585-597.
[1] Li X, Guo X, Chang Y, et al. Analysis of alterations of serum inflammatory cyto-kines and fibrosis makers in patients with essential hypertension and left ventricular hypertrophy and the risk factors[J]. Am J Transl Res, 2022, 14:4097-4103.
[2] Chen Y, Zhao Y, Yuan L, et al. Periplaneta americana extract attenuates hepatic fibrosis progression by inhibiting collagen synthesis and regulating the TGF-β1/Smad signaling pathway[J]. Folia Histochem Cytobiol, 2023, 61:231-243.
[3] Tang X, Yang L, Zhang P, et al. Occult Hepatitis B Virus Infection and Liver Fi-brosis in Chinese Patients[J]. J Infect Dis, 2023, 228:1375-1384.
[4] Diemar SS, Dahl SS, West AS, et al. A Systematic Review of the Circadian Rhythm of Bone Markers in Blood[J]. Calcif Tissue Int, 2023, 112:126-147.
[5] He Y, Gu X, Yang Z, et al. Study on the mechanism underlying Trichosanthis peel injection-induced improvements in myocardial fibrosis markers in patients with chronic heart failure[J]. Clin Exp Pharmacol Physiol, 2024, 51:e13848.
[6] Moufarrej MN, Vorperian SK, Wong RJ, et al. Early prediction of preeclampsia in pregnancy with cell-free RNA[J]. Nature, 2022, 602:689-694.
[7] Su Y, Wang W, Liu F, et al. Blosozumab in the treatment of postmenopausal women with osteoporosis: a systematic review and meta-analysis[J]. Ann Palliat Med, 2022, 11:3203-3212.
[8] Li H, Xu X, Yi T, et al. Expression of chitinase-3-like protein 1 in different TCM syndromes and its correlation with liver fibrosis[J]. Ann Palliat Med, 2022, 11:217-224.
[9] Fan J, Li Y, Yan Q, et al. Higher serum sST2 is associated with increased left atri-al low-voltage areas and atrial fibrillation recurrence in patients undergoing radiof-requency ablation[J]. J Interv Card Electrophysiol, 2022, 64:733-742.
[10] Chen XF, Ji S. Sorafenib Attenuates Fibrotic Hepatic Injury Through Mediating Lysine Crotonylation[J]. Drug Des Devel Ther, 2022, 16:2133-2144.
[11] Huang Q, Zhang K, Li Y, et al. Auto- and Hetero-Catalytic Processing of the N-Terminal Propeptide Promotes the C-Terminal Fibronectin Type III Domain-Mediated Dimerization of a Thermostable Vpr-like Protease[J]. Appl Environ Micro-biol, 2022, 88:e0150322.
[12] Matsumoto T, Sone T, Soen S, et al. Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study[J]. J Clin Endocrinol Metab, 2022, 107:e4222-e4231.
[13] Malecki-Ketchell A. Acute coronary syndrome: role of the nurse in patient as-sessment and management[J]. Nurs Stand, 2022, 37:69-75.
[14] Wang S, Meng F, Li M, et al. Multidimensional Cell-Free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer[J]. Am J Respir Crit Care Med, 2023, 207:1203-1213.
[15] Ćorović A, Wall C, Nus M, et al. Somatostatin Receptor PET/MR Imaging of Inflammation in Patients With Large Vessel Vasculitis and Atherosclerosis[J]. J Am Coll Cardiol, 2023, 81:336-354.
[16] Tokumoto M, Tokunaga S, Asada S, et al. Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism[J]. PLoS One, 2022, 17:e0279078.
[17] Gadelha MR, Gordon MB, Doknic M, et al. ACROBAT Edge: Safety and Effi-cacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly[J]. J Clin Endocrinol Metab, 2023, 108:e148-e159.
[18] Papadimitriou MA, Levis P, Kotronopoulos G, et al. Preoperative Cell-Free DNA (cfDNA) in Muscle-Invasive Bladder Cancer Treatment Outcome[J]. Clin Chem, 2023, 69:399-410.
[19] Vasikaran SD, Miura M, Pikner R, et al. Practical Considerations for the Clinical Application of Bone Turnover Markers in Osteoporosis[J]. Calcif Tissue Int, 2023, 112:148-157.
[20] Zhu Y, Pei L, Li N, et al. Preoperative sST2 levels relate to myocardial remodel-ing and cardiac function improvement after cardiac valve surgery[J]. ESC Heart Fail, 2024, 11:91-98.
[21] Chen Y, Zhao X, Liang L, et al. sST2 and Big ET-1 as Alternatives of Multi-Biomarkers Strategies for Prognosis Evaluation in Patients Hospitalized with Heart Failure[J]. Int J Gen Med, 2023, 16:5003-5016.
[22] Tang LJ, Li G, Eslam M, et al. N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD[J]. Hepatol Int, 2023, 17:190-201.
[23] Tominaga A, Wada K, Okazaki K, et al. Nonresponder Considerations for Ro-mosozumab Treatment[J]. Calcif Tissue Int, 2023, 113:157-165.
[24] Meng Q, Zhang M. Clinical Significance of Serum Collagen Type IV and Pro-collagen Type III N-Peptide Levels in Diagnosis and Differential Diagnosis of Lymphedema[J]. Lymphat Res Biol, 2023, 21:8-14.
[25] Esfahani MS, Hamilton EG, Mehrmohamadi M, et al. Inferring gene expression from cell-free DNA fragmentation profiles[J]. Nat Biotechnol, 2022, 40:585-597.
Objavljeno
2024/10/03
Broj časopisa
Rubrika
Original paper
Sva prava zadržana (c) 2024 Haoran Jia
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.